A significant driver of top-line growth: Biomarin Pharmaceutical Inc (BMRN)

With 1.19 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.55 million shares. The 52-week range on BMRN shows that it touched its highest point at $94.85 and its lowest point at $60.63 during that stretch. It currently has a 1-year price target of $97.32. Beta for the stock currently stands at 0.34.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BMRN was up-trending over the past week, with a rise of 0.57%, but this was up by 9.28% over a month. Three-month performance surged to 7.56% while six-month performance fell -23.18%. The stock lost -23.29% in the past year, while it has gained 5.16% so far this year. A look at the trailing 12-month EPS for BMRN yields 2.20 with Next year EPS estimates of 4.11. For the next quarter, that number is 0.70. This implies an EPS growth rate of 43.47% for this year and 29.78% for next year.

Float and Shares Shorts:

At present, 190.76 million BMRN shares are outstanding with a float of 188.43 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BMRN since 9 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $2.31955 being high and $2.20254 being low. For BMRN, this leads to a yearly average estimate of $2.2576. Based on analyst estimates, the high estimate for the next quarter is $1.17 and the low estimate is $0.59. The average estimate for the next quarter is thus $1.03.